The Muscular Dystrophy Association (MDA) welcomes the U.S. Food and Drug Administration (FDA) approval of the expanded indication of Alexion/AstraZeneca’s eculizumab (Soliris) for pediatric patients ...

Generalized myasthenia gravis (gMG) affects most patients through a handful of well-characterized neuromuscular junction ...

Anti-acetylcholine receptor antibody (AChR-Ab) titers and the AChR-Ab rates of change correlated with myasthenia gravis disease severity scores in a recent study. Using anti-acetylcholine receptor ...

Vyvgart attaches to a part of these antibodies, called neonatal Fc receptors (FcRn), which ... effect of Vyvgart using a test called the Myasthenia Gravis-Specific Activities of Daily Living ...

Opens in a new tab or window Recently approved treatments for generalized myasthenia gravis (gMG), including complement and neonatal Fc receptor (FcRn) inhibitors, offer a new treatment paradigm ...

Phase 2 MaGic trial of DNTH103 in generalized Myasthenia Gravis (gMG) ongoing; top-line results on track for 2H’25Phase 3 CAPTIVATE trial of ...

Seismic Therapeutic, Inc., the machine learning immunology company, today announced the dosing of the first healthy subject ...

On World Rare Diseases Day, read on to learn more about Myasthenia Gravis, a complex autoimmune disorder that requires ...

It was a study of nipocalimab plus standard of care in patients with generalized myasthenia gravis against placebo ... including anti-AChR [acetylcholine receptor], MuSK [muscle specific kinase ...